The American Medical Association, more than 90 national provider and health organizations, and national, state and medical specialty associations encouraged the Institute of Medicine to support constructive learning and shared experience in the development of a properly constructed healthcare error reporting system.
The American Medical Association, more than 90 national provider and health organizations, and national, state and medical specialty associations encouraged the Institute of Medicine to support constructive learning and shared experience in the development of a properly constructed healthcare error reporting system.
The broad coalition - which includes the American Hospital Association, the American Association of Health Plans and the Joint Commission on Accreditation of Healthcare Organizations - invited the Institute of Medicine to use "General Principles for a Patient Safety Reporting System" as a guide while it develops further reports on the quality of healthcare in the United States and recommends national measures of quality.
The groups emphasized the need to create a non-punitive culture that supports health system error reporting and analyses as positive actions to advance quality. "Otherwise, errors will continue to be hidden for fear of a punitive rather than a constructive response," the organizations said in a joint letter.
The principles also highlight the need for:
•Â Information submitted to reporting systems to be comprehensively analyzed to identify actions that would minimize the risk of reported events recurring.
•Â Confidentiality protections for patients, healthcare professionals and healthcare organizations.
•Â Increased sharing of patient safety information between healthcare organizations and collaboration between healthcare reporting systems.
•Â Clear legal protections for information submitted to patient safety reporting systems to enhance the opportunity to identify trends and implement corrective measures.
The principles previously have been shared with the National Quality Forum, Health Care Financing Administration and the Agency for Healthcare Research and Quality. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
FDA Approves Hikma’s Generic GLP-1 Agonist for Type 2 Diabetes
December 24th 2024Approval marks the first generic version of liraglutide injection, referencing Victoza, for improving glycemic control in adults and children aged 10 years and older with type 2 diabetes, alongside diet and exercise.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.